Coca-Cola FEMSA Reports Strong Q4 Performance with Revenue Growth
- Performance Growth: Coca-Cola FEMSA's total volume increased by 1.3% to 1,093.6 million unit cases in Q4 2025, despite a slight decline in Mexico, indicating strong demand across multiple regions and boosting market confidence.
- Revenue Increase: The company's revenue rose by 2.9% to Ps. 77,750 million, primarily driven by effective pricing and revenue management strategies, although currency translation and product mix effects limited overall growth.
- Operating Income Improvement: Operating income advanced by 13.3% to Ps. 13,702 million, aided in part by insurance claim recoveries in Brazil and Mexico, demonstrating the company's success in cost control and revenue management.
- Stable Net Profit: Net income attributable to shareholders climbed by 3% to Ps. 7,501 million, despite higher financing expenses and tax burdens, reflecting the company's robust financial performance and ongoing competitiveness in international markets.
Trade with 70% Backtested Accuracy
Analyst Views on KOF
About KOF
About the author
Coca-Cola Announces $1B Investment in South Africa by 2030
- Investment Overview: Coca-Cola has announced a $1 billion investment plan in South Africa by 2030, aimed at expanding production capacity, improving distribution networks, and driving product innovation, thereby enhancing its competitive edge in the local market.
- Collaborative Model: The investment will be executed jointly with local bottling partners, underscoring Coca-Cola's asset-light franchise bottling model, which further solidifies its market position in South Africa.
- Economic Contribution: According to Coca-Cola's statement, the system in South Africa contributed R51.2 billion in value-added economic activity in 2024, highlighting its significant role in promoting economic growth.
- Regional Strategy: This investment is not only a standalone project for South Africa but also aligns with Coca-Cola's broader commitments, including a $1.2 billion continental investment planned for 2025 and a $25 million water stewardship commitment by 2030, indicating a long-term commitment to the African market.
Coca-Cola FEMSA Reports Strong Q4 Performance with Revenue Growth
- Performance Growth: Coca-Cola FEMSA's total volume increased by 1.3% to 1,093.6 million unit cases in Q4 2025, despite a slight decline in Mexico, indicating strong demand across multiple regions and boosting market confidence.
- Revenue Increase: The company's revenue rose by 2.9% to Ps. 77,750 million, primarily driven by effective pricing and revenue management strategies, although currency translation and product mix effects limited overall growth.
- Operating Income Improvement: Operating income advanced by 13.3% to Ps. 13,702 million, aided in part by insurance claim recoveries in Brazil and Mexico, demonstrating the company's success in cost control and revenue management.
- Stable Net Profit: Net income attributable to shareholders climbed by 3% to Ps. 7,501 million, despite higher financing expenses and tax burdens, reflecting the company's robust financial performance and ongoing competitiveness in international markets.
Coca-Cola FEMSA to Announce Q4 Earnings on February 24
- Earnings Announcement: Coca-Cola FEMSA is set to release its Q4 earnings report on February 24 before market open, with consensus EPS estimated at $1.87 and revenue expected to reach $4.44 billion, indicating strong investor interest in the company's financial performance.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates have experienced three upward revisions with none downward, suggesting increased market confidence in the company's growth prospects, particularly in revenue.
- Market Reaction: As the earnings report approaches, investor attention on Coca-Cola FEMSA is rising, especially regarding potential gains from its operations in Venezuela, reflecting market expectations for the company's strategic positioning in emerging markets.
- Historical Performance Reference: Historical earnings data and dividend scorecards for Coca-Cola FEMSA indicate the company's performance in delivering stable returns and reasonable valuations, further bolstering investor confidence in its future financial health.
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
UBS Reiterates Buy Rating on Coca-Cola Femsa SAB de, Adjusts Price Target to $109
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Earnings Report Ahead of Market Opening for October 24, 2025: PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS
Earnings Reports Overview: Several companies, including Procter & Gamble, Sanofi, and HCA Healthcare, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Procter & Gamble Performance: PG's expected earnings per share (EPS) is $1.90, reflecting a 1.55% decrease from last year, while it has met or beaten analyst expectations in three of the last four quarters.
HCA Healthcare Growth: HCA is projected to report an EPS of $5.65, indicating an 11.88% increase year-over-year, having consistently beaten expectations in the past year.
Mixed Results Across Industries: Companies like Booz Allen Hamilton and Gentex are expected to see decreases in EPS, while others like Illinois Tool Works and First Hawaiian are forecasted to show growth, highlighting diverse performance across sectors.
Coca-Cola Announces $1B Investment in South Africa by 2030
- Investment Overview: Coca-Cola has announced a $1 billion investment plan in South Africa by 2030, aimed at expanding production capacity, improving distribution networks, and driving product innovation, thereby enhancing its competitive edge in the local market.
- Collaborative Model: The investment will be executed jointly with local bottling partners, underscoring Coca-Cola's asset-light franchise bottling model, which further solidifies its market position in South Africa.
- Economic Contribution: According to Coca-Cola's statement, the system in South Africa contributed R51.2 billion in value-added economic activity in 2024, highlighting its significant role in promoting economic growth.
- Regional Strategy: This investment is not only a standalone project for South Africa but also aligns with Coca-Cola's broader commitments, including a $1.2 billion continental investment planned for 2025 and a $25 million water stewardship commitment by 2030, indicating a long-term commitment to the African market.
Coca-Cola FEMSA Reports Strong Q4 Performance with Revenue Growth
- Performance Growth: Coca-Cola FEMSA's total volume increased by 1.3% to 1,093.6 million unit cases in Q4 2025, despite a slight decline in Mexico, indicating strong demand across multiple regions and boosting market confidence.
- Revenue Increase: The company's revenue rose by 2.9% to Ps. 77,750 million, primarily driven by effective pricing and revenue management strategies, although currency translation and product mix effects limited overall growth.
- Operating Income Improvement: Operating income advanced by 13.3% to Ps. 13,702 million, aided in part by insurance claim recoveries in Brazil and Mexico, demonstrating the company's success in cost control and revenue management.
- Stable Net Profit: Net income attributable to shareholders climbed by 3% to Ps. 7,501 million, despite higher financing expenses and tax burdens, reflecting the company's robust financial performance and ongoing competitiveness in international markets.
Coca-Cola FEMSA to Announce Q4 Earnings on February 24
- Earnings Announcement: Coca-Cola FEMSA is set to release its Q4 earnings report on February 24 before market open, with consensus EPS estimated at $1.87 and revenue expected to reach $4.44 billion, indicating strong investor interest in the company's financial performance.
- Earnings Estimate Changes: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates have experienced three upward revisions with none downward, suggesting increased market confidence in the company's growth prospects, particularly in revenue.
- Market Reaction: As the earnings report approaches, investor attention on Coca-Cola FEMSA is rising, especially regarding potential gains from its operations in Venezuela, reflecting market expectations for the company's strategic positioning in emerging markets.
- Historical Performance Reference: Historical earnings data and dividend scorecards for Coca-Cola FEMSA indicate the company's performance in delivering stable returns and reasonable valuations, further bolstering investor confidence in its future financial health.
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades
Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.
10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.
Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.
Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.
UBS Reiterates Buy Rating on Coca-Cola Femsa SAB de, Adjusts Price Target to $109
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Earnings Report Ahead of Market Opening for October 24, 2025: PG, SNY, HCA, GD, ITW, BAH, GNTX, FLG, FHB, KOF, STEL, VRTS
Earnings Reports Overview: Several companies, including Procter & Gamble, Sanofi, and HCA Healthcare, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Procter & Gamble Performance: PG's expected earnings per share (EPS) is $1.90, reflecting a 1.55% decrease from last year, while it has met or beaten analyst expectations in three of the last four quarters.
HCA Healthcare Growth: HCA is projected to report an EPS of $5.65, indicating an 11.88% increase year-over-year, having consistently beaten expectations in the past year.
Mixed Results Across Industries: Companies like Booz Allen Hamilton and Gentex are expected to see decreases in EPS, while others like Illinois Tool Works and First Hawaiian are forecasted to show growth, highlighting diverse performance across sectors.
